Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Justine Anastasia Barletta, M.D.

Co-Author

This page shows the publications co-authored by Justine Barletta and Jochen Lorch.
Connection Strength

2.559
  1. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Thyroid. 2021 06; 31(6):933-940.
    View in: PubMed
    Score: 0.229
  2. Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component. Endocr Pathol. 2020 Sep; 31(3):283-290.
    View in: PubMed
    Score: 0.223
  3. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma. Histopathology. 2020 Aug; 77(2):314-320.
    View in: PubMed
    Score: 0.221
  4. A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. Histopathology. 2020 Apr; 76(5):707-713.
    View in: PubMed
    Score: 0.217
  5. Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid. 2019 09; 29(9):1255-1261.
    View in: PubMed
    Score: 0.208
  6. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid. 2019 05; 29(5):666-673.
    View in: PubMed
    Score: 0.203
  7. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
    View in: PubMed
    Score: 0.201
  8. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
    View in: PubMed
    Score: 0.186
  9. Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018 May; 47(5):568-577.
    View in: PubMed
    Score: 0.182
  10. A case of primary secretory carcinoma of the thyroid with high-grade features. Histopathology. 2017 10; 71(4):665-669.
    View in: PubMed
    Score: 0.179
  11. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
    View in: PubMed
    Score: 0.148
  12. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer. Surgery. 2022 01; 171(1):227-234.
    View in: PubMed
    Score: 0.059
  13. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021 08 01; 27(15):4256-4264.
    View in: PubMed
    Score: 0.059
  14. Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines. Ann Surg Oncol. 2021 Jan; 28(1):484-491.
    View in: PubMed
    Score: 0.055
  15. Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer. Surgery. 2020 01; 167(1):87-93.
    View in: PubMed
    Score: 0.052
  16. The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer. J Endocr Soc. 2019 Apr 01; 3(4):791-800.
    View in: PubMed
    Score: 0.050
  17. Successful Management of a Patient with Malignant Thyroid Teratoma. Thyroid. 2017 01; 27(1):125-128.
    View in: PubMed
    Score: 0.043
  18. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clin Cancer Res. 2017 May 01; 23(9):2367-2373.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.